ROIS: The CDMO Making Waves in the US Market
The Phoenix Acquisition: A Strategic Foothold in the US Market
The global CDMO market is forecast to double by 2032—yet specialist filling capacity remains a critical bottleneck for the industry. As demand for GLP-1s, biosimilars, and ADCs explodes, securing a partner with the right scale and regulatory pedigree on American soil is no longer just an operational need; it is a strategic imperative.
Download our free article to explore why the Phoenix acquisition is a pivotal moment for ROIS, how it tackles the industry’s manufacturing bottleneck, and what this expansion means for your US-based programs.
About the Author
Kimberlee Steele is an experience life sciences executive with more than 25 years in the pharmaceutical, medical device, consulting and technology sectors. She has deep expertise in commercial leadership, strategic partnerships, and end‑to‑end drug product and drug delivery technologies, with a track record of driving growth in complex, global organisations.
